This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 2481 |
control group | 2194 |
mean age | 1775 |
mg kg | 1698 |
two groups | 1677 |
significantly higher | 1647 |
risk factors | 1400 |
significant difference | 1383 |
statistically significant | 1347 |
care unit | 1318 |
septic shock | 1290 |
mechanical ventilation | 1280 |
critically ill | 1279 |
significant differences | 1099 |
ng ml | 1023 |
years old | 1003 |
stem cell | 987 |
blood pressure | 985 |
blood donors | 964 |
one patient | 958 |
ill patients | 954 |
blood transfusion | 891 |
median age | 882 |
bone marrow | 881 |
present study | 852 |
patients admitted | 829 |
mg dl | 807 |
patients received | 788 |
significantly lower | 747 |
critical care | 730 |
performed using | 705 |
whole blood | 691 |
patients undergoing | 681 |
mortality rate | 676 |
blood group | 676 |
hospital stay | 669 |
blood samples | 666 |
cardiac arrest | 664 |
two patients | 656 |
peripheral blood | 654 |
body weight | 647 |
university hospital | 643 |
renal failure | 642 |
retrospective study | 641 |
logistic regression | 638 |
pg ml | 622 |
statistical analysis | 601 |
adverse events | 599 |
emergency department | 597 |
health care | 593 |
hospital mortality | 591 |
apache ii | 588 |
red blood | 585 |
side effects | 580 |
icu admission | 575 |
cell transplantation | 574 |
patients underwent | 562 |
renal function | 558 |
high risk | 551 |
patients treated | 550 |
gene expression | 549 |
study period | 548 |
respiratory failure | 547 |
organ failure | 540 |
acute respiratory | 535 |
risk factor | 524 |
cardiac surgery | 512 |
blood flow | 506 |
ml min | 498 |
flow cytometry | 496 |
long term | 496 |
ml kg | 495 |
icu stay | 493 |
icu patients | 491 |
lymph node | 490 |
prospective study | 490 |
summary conclusions | 489 |
cd cd | 486 |
ct scan | 480 |
blood donation | 480 |
significantly increased | 477 |
multivariate analysis | 476 |
blood components | 475 |
lymph nodes | 471 |
trauma patients | 465 |
weight loss | 462 |
adult patients | 460 |
observational study | 456 |
patients without | 452 |
cohort study | 451 |
regression analysis | 447 |
cell lines | 445 |
united states | 445 |
least one | 443 |
breast cancer | 443 |
blood cells | 440 |
severe sepsis | 439 |
consecutive patients | 439 |
immune response | 438 |
blood products | 436 |
overall survival | 435 |
red cell | 430 |
three patients | 427 |
minimally invasive | 427 |
group i | 426 |
oxidative stress | 425 |
blood cell | 422 |
heart rate | 421 |
significantly different | 420 |
results suggest | 420 |
blood loss | 418 |
case report | 417 |
clinical signs | 412 |
stem cells | 411 |
increased risk | 410 |
abdominal pain | 406 |
pet ct | 404 |
significant increase | 404 |
aft er | 401 |
patients receiving | 388 |
important role | 385 |
one year | 382 |
body mass | 381 |
year old | 381 |
included patients | 381 |
signifi cant | 380 |
septic patients | 379 |
diabetes mellitus | 378 |
pediatric patients | 378 |
inclusion criteria | 375 |
hematopoietic stem | 370 |
mechanically ventilated | 366 |
respiratory distress | 365 |
heart failure | 364 |
cd cells | 360 |
urinary tract | 360 |
among patients | 357 |
group ii | 356 |
four patients | 354 |
metabolic syndrome | 351 |
amino acid | 349 |
significantly reduced | 346 |
significantly associated | 346 |
chronic hepatitis | 345 |
statistical significance | 345 |
results showed | 341 |
old male | 340 |
insulin resistance | 335 |
informed consent | 334 |
average age | 334 |
mg ml | 334 |
median time | 334 |
treatment group | 333 |
lung injury | 331 |
day mortality | 330 |
predictive value | 327 |
determine whether | 326 |
clinical practice | 326 |
inflammatory response | 325 |
hbv dna | 323 |
serum creatinine | 322 |
retrospective analysis | 322 |
sofa score | 322 |
clinical trial | 322 |
design method | 321 |
mass index | 321 |
computed tomography | 320 |
five patients | 318 |
platelet count | 317 |
ii score | 315 |
three groups | 315 |
brain injury | 314 |
clinical trials | 314 |
care units | 312 |
arterial pressure | 312 |
left ventricular | 311 |
previous studies | 311 |
medical center | 309 |
type diabetes | 309 |
factors associated | 308 |
cardiac output | 307 |
kg day | 306 |
medical records | 306 |
year period | 305 |
replacement therapy | 305 |
one case | 305 |
first time | 302 |
measured using | 301 |
data suggest | 300 |
analysis showed | 300 |
blood glucose | 299 |
coronary artery | 298 |
significant correlation | 297 |
respiratory syndrome | 293 |
significantly decreased | 291 |
operative time | 290 |
age years | 290 |
cell line | 287 |
median follow | 287 |
specific ige | 286 |
kidney injury | 286 |
cell proliferation | 285 |
physical examination | 284 |
postoperative complications | 284 |
analyzed using | 284 |
older adults | 283 |
amino acids | 282 |
reactive protein | 282 |
organ dysfunction | 281 |
total number | 280 |
nitric oxide | 279 |
laparoscopic surgery | 278 |
prostate cancer | 275 |
arterial blood | 274 |
study included | 274 |
old female | 272 |
image quality | 272 |
cancer patients | 272 |
age group | 271 |
primary outcome | 271 |
central venous | 270 |
iu ml | 270 |
transfusion medicine | 270 |
public health | 270 |
liver disease | 268 |
study aimed | 268 |
within hours | 267 |
th day | 267 |
kidney disease | 266 |
renal replacement | 265 |
red cells | 265 |
within days | 265 |
surgical treatment | 264 |
six patients | 264 |
serum levels | 264 |
mental health | 263 |
healthy controls | 262 |
patients died | 261 |
growth factor | 259 |
free survival | 259 |
signifi cantly | 258 |
mortality rates | 258 |
heart disease | 258 |
allergic rhinitis | 257 |
immune system | 257 |
acute kidney | 256 |
study group | 255 |
antibiotic therapy | 255 |
month period | 253 |
myocardial infarction | 253 |
survival rate | 253 |
results indicate | 253 |
two different | 252 |
elderly patients | 252 |
viral load | 251 |
blood bank | 251 |
patients showed | 251 |
nephrotic syndrome | 250 |
significant reduction | 250 |
positive correlation | 250 |
bariatric surgery | 249 |
significant decrease | 249 |
blood donor | 248 |
univariate analysis | 247 |
multiple organ | 246 |
small bowel | 244 |
laparoscopic approach | 244 |
widely used | 244 |
linear regression | 244 |
time pcr | 241 |
odds ratio | 241 |
mean arterial | 241 |
preliminary results | 239 |
pulmonary artery | 239 |
severe acute | 239 |
ethics regulations | 238 |
tidal volume | 237 |
clinical data | 237 |
renal disease | 237 |
icu mortality | 236 |
seven patients | 236 |
pregnant women | 236 |
ventilated patients | 234 |
respiratory tract | 234 |
randomized controlled | 234 |
intervention group | 233 |
nk cells | 233 |
host disease | 233 |
study showed | 232 |
pao fio | 232 |
physical activity | 231 |
acute renal | 230 |
group compared | 230 |
two cases | 230 |
standard deviation | 229 |
results show | 229 |
one hundred | 229 |
bile duct | 228 |
prospective observational | 228 |
controlled trial | 228 |
commonly used | 228 |
adverse effects | 227 |
higher risk | 227 |
clinical outcomes | 226 |
last years | 226 |
distress syndrome | 226 |
pilot study | 225 |
may lead | 225 |
confidence interval | 224 |
critical illness | 223 |
streptococcal pharyngitis | 222 |
platelet concentrates | 221 |
endothelial cells | 221 |
assessed using | 220 |
postoperative day | 219 |
patients aged | 218 |
per day | 218 |
gold standard | 218 |
respiratory rate | 217 |
hcv rna | 217 |
time points | 216 |
cord uid | 216 |
gastric bypass | 216 |
previously reported | 216 |
doc id | 216 |
conditioning regimen | 216 |
liver transplantation | 216 |
gastric cancer | 216 |
two years | 215 |
epithelial cells | 214 |
eight patients | 213 |
high mortality | 213 |
age groups | 212 |
demographic data | 212 |
transplant recipients | 211 |
high levels | 211 |
clinical course | 211 |
traumatic brain | 211 |
acute phase | 210 |
saps ii | 210 |
chain reaction | 209 |
fi rst | 209 |
lung cancer | 208 |
patients developed | 208 |
general hospital | 208 |
high dose | 207 |
western blot | 206 |
patients presented | 206 |
muscle mass | 205 |
immune responses | 205 |
hospital discharge | 205 |
normal range | 204 |
colorectal cancer | 203 |
first days | 203 |
polymerase chain | 203 |
healthy volunteers | 201 |
patients presenting | 201 |
differential diagnosis | 201 |
independently associated | 200 |
soft tissue | 199 |
three months | 199 |
nine patients | 199 |
clinical outcome | 199 |
mrna expression | 198 |
nervous system | 198 |
chart review | 198 |
control groups | 197 |
regression model | 196 |
clinical features | 195 |
plasma levels | 195 |
transfusion reactions | 195 |
analysis revealed | 195 |
well tolerated | 195 |
acute gvhd | 194 |
graft survival | 194 |
prognostic factors | 193 |
rectal cancer | 193 |
general population | 192 |
chronic gvhd | 192 |
days post | 192 |
six months | 192 |
commercially available | 192 |
one month | 192 |
skeletal muscle | 190 |
per patient | 190 |
blood groups | 190 |
systematic review | 189 |
increased significantly | 189 |
current study | 189 |
poor outcome | 188 |
clinical characteristics | 188 |
protein expression | 188 |
recent years | 187 |
boko haram | 187 |
study population | 187 |
exclusion criteria | 187 |
retrospective cohort | 186 |
lg ml | 186 |
may also | 186 |
sickle cell | 185 |
first hours | 185 |
complete remission | 185 |
per year | 185 |
evaluated using | 185 |
uric acid | 184 |
clinically significant | 184 |
acute rejection | 184 |
blood gas | 184 |
copies ml | 183 |
sample size | 182 |
data collection | 182 |
blood collection | 181 |
retrospectively reviewed | 181 |
surgical procedures | 181 |
diabetic patients | 181 |
postoperative period | 180 |
oxygen saturation | 180 |
smooth muscle | 179 |
severity score | 179 |
cancer cells | 179 |
also found | 179 |
obese patients | 179 |
blood banks | 178 |
significant improvement | 178 |
tract infection | 178 |
single center | 178 |
hepatocellular carcinoma | 178 |
abdominal wall | 177 |
old woman | 177 |
cell carcinoma | 177 |
determined using | 177 |
cell count | 177 |
infectious diseases | 177 |
overall mortality | 176 |
significant association | 176 |
independent risk | 176 |
sectional study | 176 |
even though | 176 |
blood units | 176 |
sleeve gastrectomy | 175 |
higher mortality | 175 |
liver function | 175 |
low dose | 175 |
tumor cells | 174 |
white blood | 174 |
blood supply | 174 |
surgical intervention | 173 |
retrospective review | 173 |
cell death | 173 |
room temperature | 172 |
real time | 172 |
adipose tissue | 172 |
four groups | 172 |
renal transplant | 171 |
general surgery | 171 |
quality control | 171 |
surgical patients | 171 |
hernia repair | 170 |
mononuclear cells | 170 |
teaching hospital | 169 |
compared using | 169 |
type i | 169 |
ct scans | 169 |
monoclonal antibody | 169 |
showed significant | 169 |
family members | 168 |
findings suggest | 168 |
operation time | 168 |
positive results | 168 |
icu discharge | 168 |
mean duration | 168 |
kg min | 168 |
square test | 168 |
recent studies | 167 |
monoclonal antibodies | 167 |
chronic kidney | 167 |
patients suffering | 167 |
disease severity | 167 |
serum samples | 166 |
cardiac index | 166 |
common cause | 166 |
tumor necrosis | 166 |
study aims | 166 |
collected data | 166 |
high level | 165 |
necrosis factor | 165 |
success rate | 165 |
treated patients | 165 |
patients required | 164 |
well known | 164 |
grade iii | 164 |
allogeneic hematopoietic | 164 |
male patients | 164 |
survival rates | 163 |
nuclear medicine | 163 |
poor prognosis | 162 |
medical history | 162 |
type ii | 162 |
graft function | 162 |
airway pressure | 161 |
clinical findings | 161 |
colon cancer | 161 |
nucleic acid | 161 |
early diagnosis | 161 |
study shows | 160 |
clinically relevant | 160 |
placebo group | 160 |
atopic dermatitis | 160 |
increased mortality | 160 |
patients diagnosed | 159 |
renal transplantation | 159 |
one week | 158 |
months post | 158 |
ejection fraction | 158 |
correlation coefficient | 158 |
whole body | 158 |
inflammatory cytokines | 157 |
decision making | 157 |
injury severity | 156 |
mean time | 156 |
treatment groups | 156 |
blood volume | 156 |
risk patients | 156 |
chronic renal | 156 |
primary care | 156 |
renal biopsy | 155 |
two weeks | 155 |
cord blood | 155 |
graft failure | 155 |
may contribute | 154 |
acute lung | 154 |
healthy subjects | 154 |
mean follow | 154 |
group received | 154 |
food allergy | 154 |
groups according | 154 |
aged years | 154 |
mass spectrometry | 154 |
fdg pet | 153 |
laparoscopic cholecystectomy | 153 |
term follow | 153 |
high prevalence | 153 |
ex vivo | 153 |
data analysis | 153 |
skin prick | 153 |
scoring system | 152 |
cardiovascular disease | 152 |
kidney transplantation | 152 |
data collected | 152 |
systolic blood | 152 |
pulmonary hypertension | 152 |
calculated using | 151 |
states background | 151 |
investigate whether | 151 |
significant changes | 151 |
large number | 151 |
response rate | 151 |
diff erence | 151 |
decreased significantly | 151 |
medical students | 150 |
prospective cohort | 150 |
liver cirrhosis | 150 |
may help | 150 |
significantly improved | 149 |
adverse reactions | 149 |
cell cycle | 149 |
roc curve | 149 |
tertiary care | 149 |
pulmonary embolism | 149 |
grade ii | 148 |
family history | 148 |
exact test | 148 |
first year | 148 |
higher levels | 148 |
blood cultures | 147 |
clinical symptoms | 147 |
th ere | 147 |
previously described | 147 |
liver failure | 147 |
chest pain | 147 |
negative predictive | 147 |
mm hg | 146 |
patients may | 146 |
interquartile range | 146 |
patient underwent | 146 |
different types | 145 |
birth weight | 145 |
may result | 145 |
surgical procedure | 145 |
three times | 144 |
age range | 144 |
healthy dogs | 144 |
blood donations | 144 |
patients included | 144 |
three different | 144 |
spinal cord | 144 |
expression levels | 143 |
also observed | 143 |
clinical presentation | 143 |
transfusion service | 143 |
vital signs | 143 |
patients requiring | 143 |
general anesthesia | 143 |
ethics committee | 143 |
mean value | 143 |
liver biopsy | 143 |
ards patients | 143 |
positive cells | 143 |
significantly correlated | 142 |
novel coronavirus | 142 |
statistical difference | 142 |
positive patients | 142 |
molecular weight | 141 |
emergency medicine | 141 |
months later | 141 |
case series | 141 |
female patients | 141 |
cell disease | 141 |
complication rate | 140 |
gvhd prophylaxis | 140 |
viral infection | 140 |
conservative treatment | 139 |
infectious disease | 139 |
may play | 139 |
receiver operating | 139 |
acute pancreatitis | 138 |
negative correlation | 138 |
also significantly | 138 |
magnetic resonance | 138 |
animal model | 138 |
retrospective chart | 138 |
considered significant | 138 |
related complications | 138 |
time period | 138 |
patient characteristics | 138 |
patient population | 137 |
dendritic cells | 137 |
group showed | 137 |
hospital cardiac | 137 |
ten patients | 137 |
small intestine | 137 |
lactate levels | 137 |
central nervous | 137 |
clinical studies | 136 |
see table | 136 |
venous blood | 136 |
disease progression | 136 |
trauma center | 135 |
baseline characteristics | 135 |
newly diagnosed | 135 |
results obtained | 135 |
higher incidence | 135 |
leading cause | 135 |
escherichia coli | 135 |
lung function | 134 |
acute appendicitis | 134 |
virus infection | 134 |
protective effect | 134 |
weight gain | 134 |
old man | 134 |
second group | 134 |
high incidence | 134 |
fresh frozen | 134 |
medical university | 133 |
randomly assigned | 133 |
mrna levels | 133 |
gas exchange | 133 |
autologous blood | 133 |
medical treatment | 133 |
focus group | 133 |
identifi ed | 133 |
wide range | 133 |
infected patients | 133 |
fatty acids | 133 |
cell viability | 133 |
shock patients | 133 |
cancer cell | 133 |
stage renal | 133 |
glucose tolerance | 132 |
emergency room | 132 |
test results | 132 |
time point | 131 |
pulmonary disease | 131 |
may provide | 131 |
descriptive statistics | 131 |
early detection | 131 |
emergency surgery | 131 |
low risk | 131 |
upper respiratory | 131 |
prospectively collected | 130 |
primary endpoint | 130 |
selected patients | 130 |
abdominal surgery | 130 |
patient died | 130 |
diagnostic accuracy | 130 |
cell surface | 129 |
specific antibodies | 129 |
hospital admission | 129 |
median duration | 129 |
waist circumference | 128 |
blood gases | 127 |
patient care | 127 |
electron microscopy | 127 |
results demonstrate | 127 |
hemorrhagic shock | 127 |
study conducted | 126 |
treatment option | 126 |
rank test | 126 |
frozen plasma | 126 |
glomerular filtration | 126 |
viral infections | 126 |
differ significantly | 126 |
gastrointestinal tract | 126 |
pressure support | 125 |
group patients | 125 |
cardiogenic shock | 125 |
factor viii | 125 |
bacterial contamination | 125 |
total protein | 125 |
combination therapy | 125 |
glasgow coma | 125 |
major cause | 125 |
mean values | 124 |
prognostic value | 124 |
cumulative incidence | 124 |
data indicate | 124 |
patient developed | 124 |
first group | 124 |
term outcomes | 124 |
term outcome | 124 |
cardiovascular risk | 124 |
cmv reactivation | 124 |
retrospectively analyzed | 124 |
cd expression | 123 |
false positive | 123 |
multivariate logistic | 123 |
may cause | 123 |
class ii | 123 |
head injury | 122 |
united kingdom | 122 |
mitral valve | 122 |
small number | 122 |
significantly elevated | 122 |
icu length | 122 |
body temperature | 122 |
artery disease | 122 |
three days | 122 |
times higher | 121 |
spontaneous breathing | 121 |
positive predictive | 121 |
cardiopulmonary bypass | 121 |
liver injury | 121 |
clinical examination | 121 |
remaining patients | 121 |
gestational age | 121 |
learning curve | 121 |
laboratory tests | 120 |
pulmonary edema | 120 |
secondary outcomes | 120 |
patient presented | 120 |
infectious complications | 120 |
invasive ventilation | 120 |
blood culture | 120 |
years ago | 120 |
care medicine | 120 |
regression models | 119 |
antibiotic treatment | 119 |
high grade | 119 |
blood transfusions | 119 |
effective treatment | 119 |
porcine reproductive | 118 |
filtration rate | 118 |
function tests | 118 |
fl uid | 118 |
associated pneumonia | 118 |
platelet aggregation | 117 |
mg day | 117 |
copd patients | 117 |
health status | 117 |
myeloid leukemia | 117 |
eff ects | 117 |
chest ct | 116 |
hbv infection | 116 |
low levels | 116 |
hcv infection | 116 |
cognitive impairment | 116 |
wild type | 116 |
patient group | 115 |
invasive mechanical | 115 |
cd cell | 115 |
graft versus | 115 |
serum albumin | 115 |
therapeutic hypothermia | 115 |
staphylococcus aureus | 114 |
new york | 114 |
studies showed | 114 |
less likely | 114 |
tumor size | 113 |
reactive oxygen | 113 |
older people | 113 |
functional outcome | 113 |
lipid peroxidation | 113 |
surface area | 113 |
operating characteristic | 113 |
prospective studies | 113 |
operating room | 113 |
survival time | 113 |
dependent manner | 113 |
first day | 113 |
short term | 113 |
invasive surgery | 113 |
reperfusion injury | 113 |
assess whether | 113 |
neurological outcome | 113 |
year survival | 113 |
kidney transplant | 113 |
tract infections | 112 |
medical care | 112 |
ed patients | 112 |
underwent laparoscopic | 112 |
three years | 112 |
physical performance | 112 |
days later | 112 |
high frequency | 112 |
also performed | 112 |
eff ect | 112 |
significantly greater | 111 |
preliminary data | 111 |
myocardial perfusion | 111 |
month follow | 111 |
plasma samples | 111 |
right ventricular | 111 |
hiatal hernia | 111 |
pediatric intensive | 111 |
group iii | 111 |
hospital length | 111 |
creatinine clearance | 111 |
multiple myeloma | 111 |
systemic inflammatory | 111 |
analysed using | 110 |
average time | 110 |
risk group | 110 |
also showed | 110 |
lymphoblastic leukemia | 110 |
related mortality | 110 |
allogeneic stem | 110 |
open surgery | 110 |
class i | 110 |
fdg uptake | 110 |
radiation dose | 110 |
endotracheal tube | 110 |
parenteral nutrition | 110 |
wistar rats | 110 |
robotic surgery | 110 |
congestive heart | 109 |
cell lymphoma | 109 |
fold increase | 109 |
blood product | 109 |
blood safety | 109 |
diff erent | 109 |
stroke volume | 109 |
vascular resistance | 109 |
animal models | 109 |
young adults | 109 |
severe ards | 109 |
several studies | 109 |
respiratory symptoms | 109 |
within months | 109 |
body fat | 109 |
bacterial infection | 109 |
squamous cell | 109 |
cell transplant | 109 |
health problem | 108 |
healthy individuals | 108 |
platelet counts | 108 |
early stage | 108 |
first step | 108 |
glucose levels | 108 |
donor selection | 108 |
one hour | 108 |
older age | 108 |
oxygen delivery | 108 |
median number | 108 |
male patient | 107 |
treated group | 107 |
acute lymphoblastic | 107 |
patient safety | 107 |
remains unclear | 107 |
surgery patients | 107 |
case reports | 107 |
independent predictor | 107 |
versus host | 107 |
abdominal cavity | 107 |
bowel obstruction | 107 |
year follow | 107 |
future studies | 107 |
muscle strength | 106 |
fatty acid | 106 |
patient received | 106 |
clinical improvement | 106 |
blood sample | 106 |
fio ratio | 106 |
control subjects | 106 |
children aged | 105 |
patient outcomes | 105 |
controlled study | 105 |
positive samples | 105 |
patient age | 105 |
female patient | 105 |
total ige | 105 |
nutritional status | 105 |
underlying disease | 105 |
respiratory disease | 105 |
renal dysfunction | 105 |
flow rate | 105 |
patient groups | 105 |
analysis using | 104 |
syndrome virus | 104 |
surgical icu | 104 |
abo blood | 104 |
transplant patients | 104 |
significantly less | 104 |
cytokine production | 104 |
grass pollen | 104 |
control study | 104 |
clinical parameters | 104 |
allogeneic hsct | 104 |
randomly divided | 104 |
pseudomonas aeruginosa | 104 |
mean number | 104 |
serum concentrations | 103 |
blood count | 103 |
previous study | 103 |
metabolic acidosis | 103 |
patient survival | 103 |
liver fibrosis | 103 |
different groups | 103 |
radical prostatectomy | 103 |
cardiac function | 103 |
one patients | 102 |
quality improvement | 102 |
significant effect | 102 |
genomic dna | 102 |
defi ned | 102 |
node dissection | 102 |
randomly selected | 102 |
health services | 102 |
blood component | 102 |
biological activity | 102 |
grade i | 102 |
cell activation | 102 |
healthy donors | 102 |
face mask | 102 |
membrane oxygenation | 102 |
lung disease | 102 |
internal medicine | 102 |
total body | 102 |
portal vein | 102 |
allergic reactions | 101 |
inflammatory mediators | 101 |
day post | 101 |
severity scores | 101 |
diagnostic criteria | 101 |
nk cell | 101 |
beneficial effect | 101 |
rbc transfusion | 101 |
world health | 101 |
transfusion services | 101 |
first months | 101 |
grip strength | 101 |
oxygen species | 100 |
outcome measures | 100 |
cfu ml | 100 |
indocyanine green | 100 |
national blood | 100 |
identify patients | 100 |
similar results | 100 |
many patients | 100 |
protein levels | 100 |
cant diff | 100 |
hemodynamic parameters | 99 |
consecutive days | 99 |
quality assurance | 99 |
laboratory findings | 99 |
acute myeloid | 99 |
relative risk | 99 |
using two | 99 |
platelet transfusion | 99 |
bronchoalveolar lavage | 99 |
renal insufficiency | 99 |
study suggests | 99 |
extracorporeal membrane | 99 |
working group | 99 |
investigated whether | 99 |
laboratory data | 99 |
complete response | 98 |
studied patients | 98 |
enrolled patients | 98 |
blood vessels | 98 |
may improve | 98 |
antiglobulin test | 98 |
data show | 98 |
wound healing | 98 |
acute myocardial | 98 |
patients compared | 98 |
inguinal hernia | 98 |
respiratory system | 98 |
vr news | 98 |
antibody screening | 97 |
table shows | 97 |
term survival | 97 |
medical staff | 97 |
tissue samples | 97 |
plasma concentrations | 97 |
single dose | 97 |
high rate | 97 |
oxygen therapy | 97 |
patients hospitalized | 97 |
study demonstrates | 97 |
chronic obstructive | 97 |
atrial fibrillation | 97 |
resonance imaging | 97 |
predictive factors | 97 |
experimental group | 97 |
brain tissue | 97 |
higher rate | 97 |
acquired pneumonia | 97 |
anastomotic leak | 97 |
healthy control | 97 |
surgical technique | 97 |
surgical resection | 97 |
western blotting | 97 |
kidney function | 96 |
blood stem | 96 |
normal saline | 96 |
much higher | 96 |
liquid chromatography | 96 |
positively correlated | 96 |
ed visits | 96 |
two months | 95 |
first week | 95 |
pulmonary vascular | 95 |
bacterial infections | 95 |
trend towards | 95 |
blood services | 95 |
diff erences | 95 |
crp levels | 95 |
infectious bronchitis | 95 |
nosocomial infections | 94 |
significant risk | 94 |
patients experienced | 94 |
growth factors | 94 |
arterial hypertension | 94 |
urine samples | 94 |
well established | 94 |
statistical analyses | 94 |
lipid profile | 94 |
patients whose | 94 |
prone position | 94 |
pulmonary function | 94 |
end stage | 93 |
abdominal trauma | 93 |
key role | 93 |
vena cava | 93 |
transcription factor | 93 |
mouse model | 93 |
mast cell | 93 |
old girl | 93 |
injured patients | 93 |
allergic patients | 93 |
treatment options | 93 |
unrelated donor | 93 |
old boy | 92 |
higher prevalence | 92 |
first case | 92 |
kg body | 92 |
innate immune | 92 |
done using | 92 |
data obtained | 92 |
showed higher | 92 |
signaling pathway | 92 |
time spent | 92 |
controlled trials | 92 |
hospitalized patients | 92 |
significant higher | 91 |
clinical study | 91 |
positive control | 91 |
venous pressure | 91 |
peritoneal dialysis | 91 |
cox regression | 91 |
patients using | 91 |
results indicated | 91 |
phase i | 91 |
artery bypass | 91 |
marrow transplantation | 91 |
serious adverse | 91 |
nursing staff | 91 |
fl ow | 91 |
confidence intervals | 91 |
pleural effusion | 91 |
significant change | 91 |
carbon dioxide | 91 |
study design | 91 |
eff ective | 91 |
extremely rare | 90 |
adhesion molecules | 90 |
postoperative course | 90 |
molecular mechanisms | 90 |
cmv infection | 90 |
examination revealed | 90 |
five years | 90 |
medical school | 90 |
per group | 90 |
whitney test | 90 |
low grade | 90 |
two days | 90 |
coronavirus disease | 90 |
immune cells | 90 |
hiv infection | 90 |
medical icu | 90 |
hours post | 90 |
mycophenolate mofetil | 90 |
laboratory parameters | 90 |
recurrence rate | 90 |
dawley rats | 90 |
significantly better | 89 |
increased expression | 89 |
three cases | 89 |
immersive vr | 89 |
focus groups | 89 |
body composition | 89 |
blood mononuclear | 89 |
fluid resuscitation | 89 |
systemic inflammation | 89 |
chronic liver | 89 |
negative patients | 89 |
clinical manifestations | 89 |
insulin sensitivity | 89 |
mean difference | 89 |
beneficial effects | 88 |
graft loss | 88 |
post operative | 88 |
average number | 88 |
hodgkin lymphoma | 88 |
adverse outcomes | 88 |
older patients | 88 |
closely related | 88 |
care patients | 88 |
intracranial pressure | 88 |
may occur | 88 |
extracellular matrix | 88 |
postoperative pain | 88 |
way anova | 88 |
significant impact | 88 |
gram negative | 88 |
past years | 87 |
health organization | 87 |
year os | 87 |
partial response | 87 |
solid tumors | 87 |
antimicrobial therapy | 87 |
study groups | 87 |
randomized clinical | 87 |
carotid artery | 87 |
connective tissue | 87 |
continuous infusion | 87 |
prick test | 86 |
cirrhotic patients | 86 |
major complications | 86 |
rheumatic fever | 86 |
classified according | 86 |
demographic characteristics | 86 |
protein intake | 86 |
probably due | 86 |
biochemical parameters | 86 |
patient demographics | 86 |
frequently used | 86 |
model group | 86 |
fluid responsiveness | 86 |
descriptive study | 86 |
observation period | 86 |
useful tool | 86 |
positive blood | 86 |
obstructive pulmonary | 86 |
fluid balance | 86 |
interest reported | 86 |
head trauma | 86 |
developing countries | 86 |
transfusion therapy | 86 |
ischemia reperfusion | 86 |
using standard | 86 |
urine output | 85 |
health literacy | 85 |
routine use | 85 |
coma scale | 85 |
house dust | 85 |
clinical diagnosis | 85 |
least two | 85 |
high resolution | 85 |
better understanding | 85 |
prognostic factor | 85 |
within normal | 85 |
blood service | 85 |
chi square | 85 |
oxygen consumption | 85 |
acute care | 85 |
endothelial cell | 85 |
blunt trauma | 85 |
clinical significance | 85 |
liver transplant | 85 |
statistically signifi | 84 |
repeated measures | 84 |
prospective randomized | 84 |
patients reported | 84 |
quantitative analysis | 84 |
high morbidity | 84 |
induction therapy | 84 |
lung tissue | 84 |
group consisted | 84 |
complication rates | 84 |
adverse event | 84 |
expression level | 84 |
better understand | 84 |
left side | 84 |
fat diet | 84 |
supine position | 84 |
may reduce | 84 |
severe covid | 84 |
eligible patients | 84 |
coping strategies | 84 |
younger patients | 84 |
clinical setting | 83 |
cell types | 83 |
early postoperative | 83 |
influenza virus | 83 |
independent predictors | 83 |
center study | 83 |
plasma glucose | 83 |
left atrial | 83 |
patients will | 83 |
creatinine ratio | 83 |
total cholesterol | 83 |
may affect | 83 |
emergency departments | 83 |
complete blood | 83 |
serum ferritin | 83 |
sex ratio | 83 |
prick tests | 83 |
jugular vein | 83 |
major surgery | 83 |
proinflammatory cytokines | 83 |
standard treatment | 83 |
disease activity | 83 |
building blocks | 83 |
one third | 83 |
per week | 83 |
sentinel lymph | 82 |
th percentile | 82 |
brain death | 82 |
may represent | 82 |
venous catheter | 82 |
without significant | 82 |
will help | 82 |
gel electrophoresis | 82 |
obtained using | 82 |
clinical use | 82 |
bladder cancer | 82 |
retrospective observational | 82 |
remained unchanged | 82 |
treatment failure | 81 |
group members | 81 |
acute leukemia | 81 |
showed significantly | 81 |
iron deficiency | 81 |
surgical management | 81 |
liver tissue | 81 |
ige levels | 81 |
within minutes | 81 |
hazard ratio | 81 |
colorectal surgery | 81 |
statistically different | 81 |
rat model | 81 |
metastatic disease | 81 |
gamma camera | 81 |
pediatric population | 80 |
study demonstrated | 80 |
high doses | 80 |
mainly due | 80 |
using spss | 80 |
dna damage | 80 |
ventilatory support | 80 |
important factor | 80 |
right side | 80 |
gait speed | 80 |
significant positive | 80 |
first line | 80 |
final diagnosis | 80 |
written informed | 80 |
also evaluated | 80 |
statistical differences | 80 |
significantly longer | 80 |
death group | 80 |
group vs | 80 |
spect ct | 80 |
high sensitivity | 80 |
risk perception | 80 |
operative complications | 80 |
hiv aids | 79 |
mean length | 79 |
one day | 79 |
normal values | 79 |
systemic lupus | 79 |
group testing | 79 |
i ii | 79 |
four different | 79 |
cell counts | 79 |
strongly associated | 79 |
low level | 79 |
training program | 79 |
considered statistically | 79 |
donor chimerism | 79 |
healthcare workers | 79 |
one group | 79 |
published data | 79 |
first study | 78 |
single nucleotide | 78 |
fold higher | 78 |
cardiopulmonary resuscitation | 78 |
studies suggest | 78 |
dust mite | 78 |
medical record | 78 |
inflammatory markers | 78 |
young children | 78 |
cell responses | 78 |
life support | 78 |
packed red | 78 |
myeloablative conditioning | 78 |
significant morbidity | 78 |
last year | 78 |
left ventricle | 78 |
lupus erythematosus | 78 |
autologous stem | 78 |
hemolytic anemia | 78 |
hours later | 78 |
main cause | 78 |
renal tubular | 78 |
surgical site | 78 |
stage iii | 78 |
tissue injury | 77 |
czech republic | 77 |
abdominal ct | 77 |
hemolytic streptococcal | 77 |
will allow | 77 |
national health | 77 |
chronic rejection | 77 |
platelet function | 77 |
incidence rate | 77 |
social media | 77 |
good results | 77 |
immunohistochemical staining | 77 |
matched unrelated | 77 |
wound infection | 77 |
acetic acid | 77 |
hemodynamic instability | 77 |
oral administration | 77 |
surg endosc | 77 |
clinical relevance | 77 |
died due | 77 |
early phase | 77 |
post transplant | 76 |
higher rates | 76 |
operative day | 76 |
bacterial growth | 76 |
following parameters | 76 |
time interval | 76 |
respiratory infections | 76 |
therapeutic effects | 76 |
tissue damage | 76 |
clinical response | 76 |
vascular endothelial | 76 |
total rna | 76 |
cardiovascular diseases | 76 |
study including | 76 |
severe head | 76 |
successfully treated | 76 |
mean score | 76 |
group included | 76 |
myocardial ischemia | 76 |
specific igg | 76 |
binding protein | 76 |
mesenchymal stem | 76 |
chronic disease | 76 |
multicenter study | 76 |
surgical approach | 75 |
also measured | 75 |
two hours | 75 |
case history | 75 |
ct images | 75 |
cases showed | 75 |
ml vs | 75 |
twice daily | 75 |
fi ndings | 75 |
fatty liver | 75 |
news items | 75 |
potential risk | 75 |
negative bacteria | 75 |
side effect | 75 |
last follow | 75 |
organ damage | 75 |
patients suffered | 75 |
phase ii | 75 |
two methods | 75 |
including patients | 75 |
thyroid cancer | 75 |
serum level | 74 |
treatment period | 74 |
months follow | 74 |
differentially expressed | 74 |
conversion rate | 74 |
data set | 74 |
negative control | 74 |
literature review | 74 |
enteral feeding | 74 |
icu admissions | 74 |
urinary protein | 74 |
naturally occurring | 74 |
upper gi | 74 |
congenital heart | 74 |
elevated levels | 74 |
healthy children | 74 |
patient data | 74 |
using different | 74 |
two independent | 74 |
white matter | 74 |
patient satisfaction | 74 |
groups based | 74 |
discharged home | 74 |
inhibitory effect | 74 |
serious complications | 74 |
disease control | 74 |
comparative study | 74 |
red cross | 74 |
underwent surgery | 74 |
tissue oxygenation | 73 |
diastolic blood | 73 |
antiviral therapy | 73 |
higher number | 73 |
every patient | 73 |
coronary angiography | 73 |
may increase | 73 |
severe asthma | 73 |
flow cytometric | 73 |
took place | 73 |
emergency medical | 73 |
data showed | 73 |
data regarding | 73 |
pulmonary arterial | 73 |
randomized trial | 73 |
post hoc | 73 |
life threatening | 73 |
antibody titers | 73 |
chest wall | 73 |
female ratio | 72 |
level i | 72 |
seven days | 72 |
meld score | 72 |
inflammatory cells | 72 |
group system | 72 |
acute pharyngitis | 72 |
first two | 72 |
renal allograft | 72 |
increased levels | 72 |
time donors | 72 |
among groups | 72 |
structure adjuvant | 72 |
cell growth | 72 |
solid phase | 72 |
middle east | 72 |
last months | 72 |
ischemic stroke | 72 |
hemolytic group | 72 |
enteral nutrition | 72 |
university medical | 72 |
fasting glucose | 72 |
adjuvant chemotherapy | 72 |
thyroid carcinoma | 72 |
major trauma | 72 |
cd count | 72 |
scan showed | 72 |
effective rate | 72 |
daily living | 72 |
ssrna nano | 71 |
many studies | 71 |
endotracheal intubation | 71 |
patient outcome | 71 |
systolic function | 71 |
information system | 71 |
tyrosine kinase | 71 |
medical intensive | 71 |
ferritin levels | 71 |
patients needed | 71 |
surgical complications | 71 |
differed significantly | 71 |
statistically significantly | 71 |
hepatic fibrosis | 71 |
infection rate | 71 |
multiple trauma | 71 |
intracranial hypertension | 71 |
massive transfusion | 71 |
quantitative pcr | 71 |
days vs | 71 |
taken together | 71 |
body surface | 71 |
continuous variables | 70 |
intravenous drip | 70 |
iga nephropathy | 70 |
point scale | 70 |
mortality risk | 70 |
sore throat | 70 |
recent study | 70 |
patients years | 70 |
stage ii | 70 |
mast cells | 70 |
performed according | 70 |
per unit | 70 |
study using | 70 |
infected group | 70 |
term results | 70 |
transfusion practice | 70 |
european countries | 70 |
median length | 70 |
immune reconstitution | 70 |
conducted using | 70 |
cell source | 70 |
high quality | 70 |
vitro studies | 69 |
allograft rejection | 69 |
alt levels | 69 |
may reflect | 69 |
group without | 69 |
effective method | 69 |
severely injured | 69 |
blood levels | 69 |
immunosorbent assay | 69 |
trauma care | 69 |
every hours | 69 |
anastomotic leakage | 69 |
food intake | 69 |
heat shock | 69 |
cytokine levels | 69 |
health outcomes | 69 |
primary objective | 69 |
slightly higher | 69 |
transcription factors | 69 |
autosomal recessive | 69 |
bone scintigraphy | 69 |
evaluate whether | 69 |
operating time | 69 |
relatively high | 69 |
least months | 69 |
retrospectively evaluated | 69 |
false negative | 69 |
mean operative | 69 |
inflammatory bowel | 69 |
confi rmed | 69 |
every day | 69 |
grade iv | 69 |
year overall | 69 |
major role | 69 |
mean apache | 69 |
skin lesions | 69 |
made available | 68 |
residual disease | 68 |
disseminated intravascular | 68 |
donor age | 68 |
also increased | 68 |
died within | 68 |
nutritional support | 68 |
well documented | 68 |
also used | 68 |
vast majority | 68 |
background aims | 68 |
abstract withdrawn | 68 |
severe disease | 68 |
broad spectrum | 68 |
twenty patients | 68 |
categorical variables | 68 |
organ transplantation | 68 |
twelve patients | 68 |
elevated serum | 68 |
hip fracture | 68 |
barr virus | 68 |
common complication | 68 |
plasma concentration | 68 |
renal cell | 68 |
bronchitis virus | 68 |
steroid therapy | 68 |
ang ii | 68 |
control patients | 68 |
diagnostic value | 68 |
specific cd | 68 |
radiation exposure | 68 |
liver resection | 68 |
cytokine release | 68 |
lower respiratory | 68 |
lower levels | 68 |
physical function | 68 |
clinical evaluation | 68 |
inflammatory process | 68 |
blood lactate | 68 |
chronic diseases | 68 |
liver enzymes | 67 |
conditioning regimens | 67 |
identified using | 67 |
streptococcal infections | 67 |
alkaline phosphatase | 67 |
low molecular | 67 |
respiratory viruses | 67 |
immune function | 67 |
solid organ | 67 |
invasive approach | 67 |
morbidly obese | 67 |
review board | 67 |
electronic medical | 67 |
institutional review | 67 |
mcg kg | 67 |
steady state | 67 |
study will | 67 |
therapeutic effect | 67 |
failure assessment | 67 |
highly significant | 67 |
negative results | 67 |
different levels | 67 |
minimal invasive | 67 |
symptom score | 67 |
relatively low | 67 |
pediatric nephrology | 67 |
first three | 67 |
eleven patients | 67 |
clinical status | 67 |
healthcare professionals | 67 |
remained stable | 67 |
time course | 67 |
acute physiology | 67 |
receive either | 67 |
superoxide dismutase | 67 |
endothelial dysfunction | 66 |
study suggest | 66 |
cd positive | 66 |
pain score | 66 |
viral hepatitis | 66 |
bowel disease | 66 |
cell adhesion | 66 |
patients met | 66 |
significantly shorter | 66 |
control animals | 66 |
hb level | 66 |
response syndrome | 66 |
buffy coat | 66 |
cross sectional | 66 |
fasting blood | 66 |
blot analysis | 66 |
investigation results | 66 |
sofa scores | 66 |
ill children | 66 |
four cases | 66 |
fat mass | 66 |
hla antibodies | 66 |
negative impact | 66 |
reduced intensity | 66 |
corticosteroid therapy | 66 |
signaling pathways | 66 |
airway management | 66 |
significant increases | 66 |
high fat | 66 |
previously published | 66 |
hoc analysis | 66 |
apoptotic cells | 66 |
hearing loss | 66 |
severe trauma | 66 |
fecal samples | 65 |
right ventricle | 65 |
outcome measure | 65 |
burn patients | 65 |
important cause | 65 |
diagnostic tool | 65 |
two hundred | 65 |
propensity score | 65 |
previous reports | 65 |
cell function | 65 |
single centre | 65 |
year mortality | 65 |
lower incidence | 65 |
histological examination | 65 |
organ injury | 65 |
intensity conditioning | 65 |
young people | 65 |
risk stratification | 65 |
hematological malignancies | 65 |
tested using | 65 |
cardiac injury | 65 |
common bile | 65 |
multidisciplinary team | 65 |
positive effect | 65 |
will also | 65 |
rib fractures | 65 |
high affinity | 65 |
four hours | 65 |
health problems | 65 |
bl mice | 65 |
immunosuppressive therapy | 65 |
small sample | 65 |
progressive disease | 65 |
care providers | 65 |
blood centers | 65 |
spatial resolution | 65 |
line treatment | 65 |
stage i | 65 |
among children | 65 |
multivariable logistic | 65 |
skin test | 65 |
safe blood | 65 |
curve analysis | 65 |
showed increased | 64 |
laparoscopic sleeve | 64 |
respiratory syncytial | 64 |
expiratory pressure | 64 |
case study | 64 |
last decade | 64 |
postoperative morbidity | 64 |
analysis demonstrated | 64 |
serum hbv | 64 |
symptom onset | 64 |
total patients | 64 |
early post | 64 |
syncytial virus | 64 |
total gastrectomy | 64 |
unrelated donors | 64 |
glucose metabolism | 64 |
clinical management | 64 |
identified patients | 64 |
median survival | 64 |
gut microbiota | 64 |
study evaluated | 64 |
heart surgery | 64 |
intravascular coagulation | 64 |
cell culture | 64 |
respiratory support | 64 |
infected cases | 64 |
patients transplanted | 64 |
clinical conditions | 64 |
care system | 64 |
respiratory infection | 64 |
gastroesophageal reflux | 64 |
donate blood | 64 |
elective surgery | 64 |
estimated blood | 63 |
sequential organ | 63 |
hematologic malignancies | 63 |
hematopoietic cell | 63 |
relapse mortality | 63 |
also known | 63 |
prone positioning | 63 |
declare background | 63 |
iron overload | 63 |
cd ra | 63 |
first report | 63 |
adhesion molecule | 63 |
significant relationships | 63 |
last two | 63 |
high degree | 63 |
pearson correlation | 63 |
interstitial fibrosis | 63 |
organ donation | 63 |
per month | 63 |
cystic duct | 63 |
clinical efficacy | 63 |
also associated | 63 |
renal impairment | 63 |
hong kong | 63 |
urinary bladder | 63 |
supportive care | 63 |
growth hormone | 63 |
significant relationship | 63 |
streptococcus pyogenes | 63 |
male wistar | 63 |
early stages | 63 |
lymphocyte count | 63 |
tolerance test | 63 |
blood banking | 63 |
social support | 63 |
pediatric oncology | 63 |
natural killer | 62 |
lower extremity | 62 |
inferior vena | 62 |
i group | 62 |
cutoff value | 62 |
cerebral blood | 62 |
estimated using | 62 |
gene therapy | 62 |
patients enrolled | 62 |
stromal cells | 62 |
clinical decision | 62 |
limited data | 62 |
trauma registry | 62 |
tumor cell | 62 |
study revealed | 62 |
factors affecting | 62 |
acute graft | 62 |
day survival | 62 |
wilcoxon rank | 62 |
signal transduction | 62 |
total effective | 62 |
voluntary blood | 62 |
significant negative | 62 |
patients achieved | 62 |
femoral neck | 62 |
patients referred | 62 |
randomised controlled | 62 |
good correlation | 62 |
light microscopy | 62 |
bronchial asthma | 62 |
observational cohort | 62 |
single institution | 62 |
african american | 62 |
increasing number | 62 |
within one | 62 |
treatment response | 62 |
skin tests | 62 |
glycemic control | 62 |
treated cells | 62 |
local recurrence | 62 |
health professionals | 62 |
total score | 62 |
renal injury | 61 |
normal renal | 61 |
gastric emptying | 61 |
portal hypertension | 61 |
total bilirubin | 61 |
detection rate | 61 |
common causes | 61 |
using flow | 61 |
allergic diseases | 61 |
standard deviations | 61 |
acute abdomen | 61 |
ten years | 61 |
converting enzyme | 61 |
health workers | 61 |
emergency physicians | 61 |
mediated rejection | 61 |
cancer surgery | 61 |
protein level | 61 |
may influence | 61 |
four weeks | 61 |
mean ae | 61 |
randomized study | 61 |
abdominal ultrasound | 61 |
standard therapy | 61 |
study protocol | 61 |
significant role | 61 |
initial treatment | 61 |
regression analyses | 61 |
foreign body | 61 |
functional status | 61 |
enzyme activity | 61 |
cystic fibrosis | 61 |
severe complications | 61 |
examination showed | 61 |
cytokine storm | 61 |
serum concentration | 61 |
internal fixation | 61 |
ug ml | 61 |
mg daily | 61 |
disease status | 60 |
effi cacy | 60 |
may benefit | 60 |
potential therapeutic | 60 |
pain control | 60 |
young patients | 60 |
peptic ulcer | 60 |
survival analysis | 60 |
higher proportion | 60 |
incisional hernia | 60 |
partial nephrectomy | 60 |
complement activation | 60 |
lactic acid | 60 |
chronic pain | 60 |
anterior resection | 60 |
linked immunosorbent | 60 |
therapeutic approach | 60 |
cardiac disease | 60 |
remains controversial | 60 |
national university | 60 |
reference range | 60 |
differences among | 60 |
activated protein | 60 |
clinical condition | 60 |
roc curves | 60 |
kg bw | 60 |
control dogs | 60 |
data suggests | 60 |
reach statistical | 60 |
dose reduction | 60 |
fungal infection | 60 |
secondary endpoints | 60 |
alanine aminotransferase | 60 |
results demonstrated | 60 |
femoral artery | 60 |
treatment modality | 60 |
skin testing | 60 |
receptor antagonist | 60 |
graft rejection | 60 |
log copies | 60 |
cell transfusion | 60 |
complications occurred | 60 |
female donors | 60 |
scoring systems | 60 |
blood center | 60 |
good clinical | 59 |
odds ratios | 59 |
inflammatory responses | 59 |
positive rate | 59 |
support ventilation | 59 |
will provide | 59 |
higher compared | 59 |
open reduction | 59 |
gas analysis | 59 |
four years | 59 |
findings indicate | 59 |
bile ducts | 59 |
radiation therapy | 59 |
four times | 59 |
poorly understood | 59 |
following criteria | 59 |
treated conservatively | 59 |
higher level | 59 |
femoral head | 59 |
spontaneous circulation | 59 |
weeks later | 59 |
multivariable analysis | 59 |
matched sibling | 59 |
good outcome | 59 |
cerebral perfusion | 59 |
hypertensive patients | 59 |
clinical history | 59 |
positive cases | 59 |
innate immunity | 59 |
esophageal pressure | 59 |
baseline values | 59 |
left hand | 59 |
younger age | 59 |
asthma control | 59 |
high blood | 59 |
traumatic stress | 59 |
undergoing cardiac | 59 |
statistical significant | 59 |
without evidence | 59 |
circulatory failure | 59 |
host response | 59 |
veterinary medicine | 58 |
plasma membrane | 58 |
dose dependent | 58 |
multiple linear | 58 |
respiratory mechanics | 58 |
without complications | 58 |
complete resolution | 58 |
chronic inflammation | 58 |
international congresses | 58 |
improve patient | 58 |
made using | 58 |
mean bmi | 58 |
pain management | 58 |
gleason score | 58 |
non invasive | 58 |
syndrome coronavirus | 58 |
old patient | 58 |
drug use | 58 |
routinely used | 58 |
molecular biology | 58 |
blood sampling | 58 |
treatment strategies | 58 |
needle aspiration | 58 |
also determined | 58 |
months following | 58 |
transit time | 58 |
russian federation | 58 |
neutrophil engraftment | 58 |
study also | 58 |
main outcome | 58 |
inflammatory diseases | 58 |
direct antiglobulin | 58 |
generation sequencing | 58 |
safety profile | 58 |
biopsy showed | 58 |
high number | 58 |
study provides | 58 |
muscle weakness | 58 |
general icu | 58 |
multiple regression | 58 |
early identification | 57 |
asthma symptoms | 57 |
cox proportional | 57 |
high volume | 57 |
showed high | 57 |
samples obtained | 57 |
antimicrobial resistance | 57 |
nasal spray | 57 |
experimental study | 57 |
least days | 57 |
surgical outcomes | 57 |
lower urinary | 57 |
detection limit | 57 |
renal artery | 57 |
promising results | 57 |
preliminary study | 57 |
risk reduction | 57 |
median value | 57 |
drug resistance | 57 |
visual analogue | 57 |
serum alt | 57 |
lung transplantation | 57 |
fluid administration | 57 |
therapeutic strategies | 57 |
fully automated | 57 |
body condition | 57 |
second patient | 57 |
type diabetic | 57 |
samples collected | 57 |
data will | 57 |
showed similar | 57 |
tumor growth | 57 |
tertiary hospital | 57 |
longer duration | 57 |
two consecutive | 57 |
new therapeutic | 57 |
tertiary referral | 57 |
retrospectively analysed | 57 |
donor blood | 57 |
received either | 57 |
identify factors | 57 |
reported cases | 57 |
patients following | 57 |
mean hospital | 57 |
may explain | 56 |
sentinel node | 56 |
oral glucose | 56 |
protein kinase | 56 |
improved significantly | 56 |
coronary heart | 56 |
superior mesenteric | 56 |
rbc units | 56 |
high rates | 56 |
mean body | 56 |
cell subsets | 56 |
quantitative real | 56 |
postoperative complication | 56 |
also assessed | 56 |
positive result | 56 |
several factors | 56 |
increased morbidity | 56 |
nan title | 56 |
average length | 56 |
therapeutic intervention | 56 |
serum total | 56 |
south korea | 56 |
intestinal obstruction | 56 |
treatment protocol | 56 |
improved survival | 56 |
liver biopsies | 56 |
complications related | 56 |
multivariate analyses | 56 |
days following | 56 |
ii scores | 56 |
antibody levels | 56 |
bypass surgery | 56 |
response rates | 56 |
cells showed | 56 |
disease free | 56 |
cerebrospinal fluid | 56 |
hemodynamically stable | 56 |
different age | 56 |
acute cholecystitis | 56 |
patients completed | 56 |
tissue perfusion | 56 |
cause mortality | 56 |
sixteen patients | 56 |
marrow failure | 56 |
surgical intensive | 56 |
intravenous injection | 56 |
patients respectively | 56 |
may serve | 56 |
burn injury | 56 |
different methods | 56 |
nosocomial infection | 56 |
cell lung | 56 |
pain scores | 56 |
tested positive | 56 |
low incidence | 55 |
creatinine level | 55 |
ms ms | 55 |
throat cultures | 55 |
signal intensity | 55 |
creatinine levels | 55 |
expiratory flow | 55 |
day pi | 55 |
small cell | 55 |
fibrin glue | 55 |
also recorded | 55 |
physical exam | 55 |
controlled clinical | 55 |
authors declare | 55 |
severe tbi | 55 |
recombinant human | 55 |
compartment syndrome | 55 |
autoimmune diseases | 55 |
excluded patients | 55 |
mobility group | 55 |
rich plasma | 55 |
high energy | 55 |
group versus | 55 |
trauma centers | 55 |
adverse reaction | 55 |
survival group | 55 |
poor outcomes | 55 |
social distancing | 55 |
patients older | 55 |
study performed | 55 |
less frequent | 55 |
prothrombin time | 55 |
fluid challenge | 55 |
patient showed | 55 |
production process | 55 |
quality management | 55 |
chest tube | 55 |
proliferative activity | 55 |
premature infants | 55 |
machine learning | 55 |
therapeutic options | 55 |
three consecutive | 55 |
inflammatory cytokine | 55 |
rheumatoid arthritis | 55 |
screening tool | 55 |
clinical information | 55 |
transplanted patients | 55 |
high serum | 55 |
higher values | 55 |
data sets | 55 |
ct findings | 55 |
reflux disease | 54 |
hiv positive | 54 |
admitted patients | 54 |
ct imaging | 54 |
patients submitted | 54 |
deficient mice | 54 |
may allow | 54 |
curative treatment | 54 |
mesenteric artery | 54 |
two decades | 54 |
density lipoprotein | 54 |
test group | 54 |
lactate level | 54 |
blood tests | 54 |
following treatment | 54 |
strong correlation | 54 |
every months | 54 |
transfusion reaction | 54 |
sialic acid | 54 |
defined according | 54 |
new approach | 54 |
aplastic anemia | 54 |
icu los | 54 |
high flow | 54 |
past medical | 54 |
groups using | 54 |
cancer treatment | 54 |
subgroup analysis | 54 |
crucial role | 54 |
internal jugular | 54 |
show significant | 54 |
grass carp | 54 |
scansystem tm | 54 |
normal limits | 54 |
upper gastrointestinal | 54 |
assessment tool | 54 |
mean weight | 54 |
first episode | 54 |
dex group | 54 |
many cases | 54 |
chb patients | 54 |
sum test | 54 |
data support | 54 |
mean serum | 54 |
wallis test | 54 |
also examined | 54 |
risk assessment | 54 |
allowed us | 54 |
altman analysis | 54 |
severe patients | 53 |
negative pressure | 53 |
gamma probe | 53 |
genes involved | 53 |
cell differentiation | 53 |
i trauma | 53 |
right lower | 53 |
site infection | 53 |
hours following | 53 |
cell survival | 53 |
situ hybridization | 53 |
severe thrombocytopenia | 53 |
hsct recipients | 53 |
allograft survival | 53 |
plasma exchange | 53 |
results will | 53 |
undergoing elective | 53 |
liver diseases | 53 |
test showed | 53 |
failure due | 53 |
years period | 53 |
significantly related | 53 |
background adaptation | 53 |
morbid obesity | 53 |
groups showed | 53 |
five cases | 53 |
murine model | 53 |
related quality | 53 |
mean blood | 53 |
treated groups | 53 |
wide variety | 53 |
limited number | 53 |
purchase intensity | 53 |
hydrogen peroxide | 53 |
male female | 53 |
laparoscopic repair | 53 |
treated rats | 53 |
airway inflammation | 53 |
wall thickness | 53 |
high percentage | 53 |
monoclonal anti | 53 |
risk groups | 53 |
right hemicolectomy | 53 |
transfused patients | 53 |
hepatic artery | 53 |
national institute | 53 |
using chi | 53 |
making process | 53 |
diagnostic laparoscopy | 53 |
progenitor cells | 53 |
inhibitory activity | 53 |
oncology patients | 53 |
marrow transplant | 53 |
except one | 53 |
previously shown | 53 |
wilcoxon signed | 53 |
gastric mucosa | 53 |
endothelial growth | 53 |
free radical | 53 |
additional information | 52 |
glucose level | 52 |
aspiration pneumonia | 52 |
treatment modalities | 52 |
outcome data | 52 |
likely due | 52 |
care services | 52 |
elisa kit | 52 |
allogeneic blood | 52 |
breast carcinoma | 52 |
still remains | 52 |
white cell | 52 |
high school | 52 |
right atrium | 52 |
medical faculty | 52 |
column agglutination | 52 |
transforming growth | 52 |
treated animals | 52 |
segmental glomerulosclerosis | 52 |
lung volume | 52 |
related symptoms | 52 |
international guidelines | 52 |
potential role | 52 |
healthy cats | 52 |
also studied | 52 |
partial remission | 52 |
higher percentage | 52 |
may indicate | 52 |
rank sum | 52 |
muscle cells | 52 |
health insurance | 52 |
less invasive | 52 |
first patient | 52 |
animal studies | 52 |
gi tract | 52 |
two types | 52 |
kg iv | 52 |
procedures performed | 52 |
method using | 52 |
dna levels | 52 |
selection criteria | 52 |
fine needle | 52 |
larger number | 52 |
serum il | 52 |
experimental studies | 52 |
antigen expression | 52 |
ventricular function | 52 |
immunocompromised patients | 52 |
partial pressure | 52 |
automated solid | 52 |
streptococcal pharyngotonsillitis | 52 |
also included | 52 |
right upper | 52 |
cell membrane | 52 |
patient required | 52 |
clinical experience | 52 |
center experience | 52 |
free radicals | 52 |
diffi cult | 52 |
lower limb | 51 |
storage time | 51 |
platelets stored | 51 |
cell dose | 51 |
clinical picture | 51 |
significance level | 51 |
next generation | 51 |
immunosuppressive treatment | 51 |
base excess | 51 |
significant correlations | 51 |
new zealand | 51 |
donor screening | 51 |
information regarding | 51 |
group participants | 51 |
currently available | 51 |
ae sd | 51 |
essential oil | 51 |
retrospective case | 51 |
splenic injury | 51 |
new method | 51 |
medical therapy | 51 |
indirect antiglobulin | 51 |
years later | 51 |
ko mice | 51 |
acid levels | 51 |
multivariate regression | 51 |
patients survived | 51 |
low hb | 51 |
kg hr | 51 |
iu kg | 51 |
intestinal microbiota | 51 |
higher doses | 51 |
cardiovascular events | 51 |
pct levels | 51 |
treg cells | 51 |
detected using | 51 |
major risk | 51 |
st day | 51 |
tidal volumes | 51 |
weeks post | 51 |
epithelial cell | 51 |
copy number | 51 |
stimulating factor | 51 |
either group | 51 |
end point | 51 |
acute coronary | 51 |
second day | 51 |
average duration | 51 |
one dog | 51 |
term effects | 51 |
rare disease | 51 |
study investigated | 51 |
muscle actin | 51 |
one study | 51 |
peritoneal cavity | 51 |
postoperative hospital | 51 |
knowledge creation | 51 |
university hospitals | 51 |
folic acid | 51 |
likert scale | 51 |
acute liver | 51 |
study found | 51 |
troponin i | 50 |
node metastases | 50 |
patients infected | 50 |
protecting groups | 50 |
future research | 50 |
common clinical | 50 |
studies using | 50 |
platelet engraftment | 50 |
groups regarding | 50 |
matched healthy | 50 |
highly sensitive | 50 |
mixed venous | 50 |
individual patient | 50 |
ct angiography | 50 |
worse prognosis | 50 |
energy expenditure | 50 |
normal controls | 50 |
serum lactate | 50 |
clinical application | 50 |
hcv genotype | 50 |
fetal dna | 50 |
clinical variables | 50 |
cd foxp | 50 |
serious complication | 50 |
within weeks | 50 |
renal involvement | 50 |
often associated | 50 |
medical patients | 50 |
health system | 50 |
ventilator settings | 50 |
buffy coats | 50 |
relapse rate | 50 |
normal serum | 50 |
control rats | 50 |
short time | 50 |
long time | 50 |
adverse effect | 50 |
reference interval | 50 |
evidence suggests | 50 |
contrast enhancement | 50 |
binding sites | 50 |
vascular permeability | 50 |
much lower | 50 |
functional outcomes | 50 |
septic complications | 50 |
rhd gene | 50 |
staple line | 50 |
prospectively studied | 50 |
linear mixed | 50 |
biopsy specimens | 50 |
cell depletion | 50 |
tracheal intubation | 50 |
per minute | 50 |
correlation coefficients | 50 |
elderly group | 50 |
blood sugar | 50 |
levels decreased | 49 |
using high | 49 |
five days | 49 |
serum ige | 49 |
nucleic acids | 49 |
liver damage | 49 |
factors related | 49 |
intubated patients | 49 |
groups i | 49 |
significant proportion | 49 |
urea nitrogen | 49 |
patients also | 49 |
visual acuity | 49 |
known risk | 49 |
per cent | 49 |
improve survival | 49 |
developed countries | 49 |
reverse transcription | 49 |
klebsiella pneumoniae | 49 |
every weeks | 49 |
samples taken | 49 |
also analyzed | 49 |
three weeks | 49 |
bypass grafting | 49 |
results suggested | 49 |
many different | 49 |
enzyme activities | 49 |
specific antibody | 49 |
increased serum | 49 |
blood type | 49 |
patient management | 49 |
significant number | 49 |
first weeks | 49 |
infectious agents | 49 |
time consuming | 49 |
artery catheter | 49 |
arachidonic acid | 49 |
north america | 49 |
bone mineral | 49 |
requiring mechanical | 49 |
hemoglobin level | 49 |
acute abdominal | 49 |
serum cobalamin | 49 |
plasma cells | 49 |
internal hernia | 49 |
higher frequency | 49 |
group receiving | 49 |
therapeutic target | 49 |
mixed chimerism | 49 |
increased incidence | 49 |
least hours | 49 |
allergic reaction | 48 |
care workers | 48 |
pulse pressure | 48 |
th postoperative | 48 |
required mechanical | 48 |
coagulation factors | 48 |
performance status | 48 |
randomized trials | 48 |
hepatic failure | 48 |
acute exacerbation | 48 |
valve disease | 48 |
stable disease | 48 |
also noted | 48 |
gastrointestinal disease | 48 |
immune cell | 48 |
using logistic | 48 |